Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of nab-paclitaxel + platinum + bevacizumab + sintilimab in advanced or recurrent cervical and endometrial cancer
ChiCTR2100049267Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Apr 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, cisplatin, carboplatin, bevacizumab and sintilimab in Cervical Cancer (CC) and endometrial cancer (EC), sponsored by Shandong Cancer Hospital. Primary endpoint: objective response rate. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
paclitaxelcisplatincarboplatinbevacizumabsintilimab
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2100049267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049267.